This robust stromal immune response, which is more prominent in TNBC due to its higher immunogenicity compared to ER+HER2– BC [33, 56], can restrict tumor growth even without tumor core infiltration, contributing to better survival outcomes in TNBC [60–62]. The gene discussed is ERBB2; the disease is breast cancer.